GSK Reports Strong Q1, Major Zantac Legal Wins, and Key Pipeline Acquisitions

summarizeSummary

GSK announced robust first-quarter results, significant legal victories in Zantac litigation, and strategic acquisitions to bolster its pipeline, reaffirming its full-year guidance.

check_boxKey Events

• Strong Q1 Financial Performance

  GSK reported Q1 sales of £7.6 billion, up 5% at constant exchange rates (CER), with Core Operating Profit increasing 10% CER to £2.65 billion and Core EPS rising 9% CER to 46.5p. The company reaffirmed its full-year 2026 guidance for turnover growth of 3% to 5% and Core operating profit and EPS growth of 7% to 9%.

• Major Zantac Legal Victories

  The Delaware Superior Court granted summary judgment for GSK in all Zantac cases filed on or before December 1, 2025, and the Zantac securities class action lawsuit was dismissed with prejudice. These rulings significantly reduce the company's litigation risk related to Zantac.

• Strategic Pipeline Acquisitions

  GSK completed the acquisition of RAPT Therapeutics for $2.3 billion, adding ozureprubart for food allergies, and 35Pharma Inc. for $950 million, acquiring HS235 for pulmonary hypertension. These acquisitions bolster GSK's pipeline with high-potential assets.

• Key Regulatory Progress

  Regulatory filings for bepirovirsen, a potential functional cure for chronic hepatitis B, were accepted in the US, EU, China, and Japan, with a US PDUFA date set for October 26, 2026. Additionally, efimosfermin received US Breakthrough and EU PRIME designations for liver disease MASH.

auto_awesomeAnalysis

GSK's first-quarter performance exceeded expectations with strong growth in Specialty Medicines, driving overall sales and core operating profit. Crucially, the company achieved major legal victories, including the dismissal of all Zantac cases in Delaware and the Zantac securities class action, significantly de-risking a long-standing overhang. Furthermore, GSK expanded its pipeline through the acquisition of RAPT Therapeutics for $2.3 billion and 35Pharma Inc. for $950 million, adding promising assets in food allergies and pulmonary hypertension. Regulatory submissions for bepirovirsen in multiple regions and breakthrough designations for efimosfermin highlight continued R&D progress. While full-year guidance was reaffirmed, the combination of strong operational performance, substantial legal de-risking, and strategic pipeline expansion provides a strong positive signal for investors.